PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Psychopharmacology (Berl). Author manuscript; available in PMC 2017 May 1.
Published in final edited form as:
PMCID: PMC4846529
NIHMSID: NIHMS753157

Mechanisms of the psychostimulant effects of caffeine: Implications for substance use disorders

Abstract

Background

The psychostimulant properties of caffeine are reviewed and compared with those of prototypical psychostimulants, able to cause substance use disorders (SUD). Caffeine produces psychomotor activating, reinforcing and arousing effects, which depend on its ability to disinhibit the brake that endogenous adenosine imposes on the ascending dopamine and arousal systems.

Objectives

A model that considers the striatal adenosine A2A-dopamine D2 receptor heteromer as a key modulator of dopamine-dependent striatal functions (reward-oriented behavior and learning of stimulus-reward and reward-response associations) is introduced, which should explain most of the psychomotor and reinforcing effects of caffeine.

Highlights

The model can explain the caffeine-induced rotational behavior in rats with unilateral striatal dopamine denervation and the ability of caffeine to reverse the adipsic-aphagic syndrome in dopamine-deficient rodents. The model can also explain the weaker reinforcing effects and low abuse liability of caffeine, compared with prototypical psychostimulants. Finally the model can explain the actual major societal dangers of caffeine: the ability of caffeine to potentiate the addictive and toxic effects of drugs of abuse, with the particularly alarming associations of caffeine (as adulterant) with cocaine, amphetamine derivatives and synthetic cathinones and energy drinks with alcohol; and the higher sensitivity of children and adolescents to the psychostimulants effects of caffeine and its possible increase in the vulnerability to develop SUD.

Conclusions

The striatal A2A-D2 receptor heteromer constitutes an unequivocal main pharmacological target of caffeine and provides the main mechanisms by which caffeine potentiates the acute and long-term effects of prototypical psychostimulants.

Keywords: Caffeine, psychostimulants, adenosine, dopamine, receptor heteromer, drug abuse, alcohol

Caffeine, the most consumed psychoactive drug in the world

Caffeine is the most consumed psychoactive drug in the world. In the United States, 87% of children and adults regularly consume foods and beverages containing caffeine (Frary et al. 2005). As discussed in the present review, its extraordinary frequent and widespread use depends on its unique psychostimulant properties. It has long been recognized that caffeine is a psychostimulant with milder pharmacological effects that prototypical psychostimulants, like amphetamine and cocaine. The terms ‘psychostimulant’ or ‘psychomotor stimulant’ are to be distinguished from ‘general central nervous system stimulant’ such as strychnine and pentylenetetrazol or picrotoxin, antagonists of the inhibitory neurotransmitter receptors for glycine and GABA, respectively (Huang et al. 2001; Dutertre et al. 2012). Psychomotor activation is a major pharmacological effect of psychostimulants, while general central nervous system stimulants fail to increase psychomotor activity at doses below those that produce convulsions. As elaborated in the following chapter, psychomotor activation implies a behavioral response in response to specific environmental stimuli, more specifically reinforcing stimuli. And, in addition to induce psychomotor activation, psychostimulants have reinforcing and arousing effects. It is one of the tenets of the present review that these three pharmacological effects contribute to caffeine use.

Psychostimulants elicit their psychomotor activating and reinforcing effects by their ability to increase central dopamine neurotransmission (see next chapter). Since caffeine is a non-selective competitive antagonist for adenosine A1 and A2A receptors (Fredholm et al. 1999), long-standing challenges have been to determine the ability of adenosine to modulate central dopamine neurotransmission and the mechanisms by which blockade of adenosine neurotransmission leads to the psychostimulant effects of caffeine. A large number of experimental data indicates that heteromers of A2A and dopamine D2 receptors localized in a specific striatal neuronal population are largely responsible for the integration of central adenosine and dopamine neurotransmission that is involved in the psychomotor and reinforcing effects of caffeine. Another tenet of the present review is that the functional and pharmacological properties of striatal A2A-D2 receptor heteromers can explain a large component of what it should be considered as the major societal dangers of caffeine, particularly the ability of caffeine to potentiate the addictive and toxic effects of drugs of abuse and the special sensitivity of children and adolescents to the psychostimulant effects of caffeine with its potential increase vulnerability to substance use disorders (SUD).

Wise and Bozarth’s Psychomotor Stimulant Theory of Addiction and Ungerstedt’s Ph.D. Thesis

In their most influential ‘Psychomotor Stimulant Theory of Addiction’, Wise and Bozarth (1987) postulated that psychomotor activation and reinforcing effects constitute different aspects of the same underlying mechanism: an increase in central dopamine neurotransmission. In their seminal paper, Wise and Bozarth (1987) eloquently extended the theory of Glickman and Schiff (1967), which holds that all positive reinforcers should elicit approach to localized stimuli or some generalized form of forward locomotion, to the case of addictive drugs.

Wise and Bozarth first elaborated on the distinction between ‘psychomotor’ and simply ‘motor’ responses. The two most commonly identified psychostimulant-induced psychomotor responses in the experimental animal are ‘locomotion’ and ‘stereotypy’. It is generally but faultily accepted that forward locomotion and stereotypy induced by psychostimulants are motor responses that result from increased dopamine transmission in the ventral striatum (nucleus accumbens), and the dorsal striatum (caudate-putamen), respectively. Both types of responses have a characteristic dependence on environmental stimuli and what psychostimulants do is to produce an increased responsiveness to those stimuli (Miller and Beninger 1991). The opposite is seen with genetic or pharmacological blockade of dopamine (Wise and Bozarth 1987; Szcypka et al. 2001) or with selective lesions of the ascending dopamine pathways or targeted dopamine denervation of striatal areas (Ljungberg and Ungerstedt 1976; Marshall et al. 1980; Miyashita et al. 1995), where the animals develop sensory neglect, inattention to relevant stimuli, rather than a simple motoric or sensory impairment.

In 1971, Urban Ungerstedt published one of the most influential Ph.D. thesis ever written in the field of Neuroscience (Ungerstedt 1971a,b,c,d). He described in detail the mapping of the monoaminergic systems and demonstrated the functional effects of unilateral or bilateral selective lesions (with 6-hydroxydopamine; 6-OHDA) of the ascending dopamine systems. With a device he invented to quantify rotational behavior in rats with unilateral 6-OHDA lesions, the rotometer, he established what was later known as ‘Ungerstedt’s method’, which became a very useful model to screen drugs with potential antiparkinsonian activity. The most striking finding was the qualitative difference between an indirect dopamine receptor agonist like amphetamine, which induces large increases of extracellular dopamine, and a direct dopamine receptor agonist like apomorphine, which directly activates dopamine receptors. Amphetamine and apomorphine produced completely opposite behaviors, with strong rotational behavior ipsilateral and contralateral to the lesioned side, respectively (Ungerstedt 1971b,c). Finally, he found that a bilateral lesion of the ascending dopamine systems reproduces the previously described ‘lateral hypothalamic syndrome’, characterized by aphagia and adipsia (Teitelbaum and Epstein 1962). The symptoms were exactly the same as those reported from more recent studies in genetic dopamine-deficient animals (Ungerstedt 1971d; Palmiter 2008). In both cases the animals have to be tube-fed or administered direct dopamine receptor agonists to reverse their symptoms in order to survive and, in both cases, they showed pronounced hypokinesia (Ungersted 1971d; Palmiter 2008).

Ungerstedt wrote: “…the role of the striatum is in all probability not one of regulating eating and drinking specifically. When considering the curious hypokinesia, lack of exploratory behavior and difficulty to initiate activity that occurs after selective lesions of the nigro-striatal dopamine system it is more probable the dopamine system and the striatum control a general arousal or drive level that is necessary for performing a number of activities, where eating and drinking deficits are noticed only because they are easily measured by the observer and disastrous to the animal” (Ungerstedt 1971d). Subsequent studies showed that impaired orientation to sensory stimuli constitutes a predominant deficit after lesioning the ascending dopamine systems, particularly the nigro-striatal system, or its striatal target area (Ljungberg and Ungerstedt 1976; Marshall et al. 1980). In fact, Marshall et al. (1971) had shown that unilateral lateral hypothalamic lesions in rats produce deficits in orientation to contralateral visual, olfactory, whisker-touch and somatosensory stimuli. It follows that turning behavior induced by dopamine agonists in unilateral 6-OHDA lesioned rats is not the result of an asymmetrical dopamine activation of locomotor mechanisms, but that of an asymmetrical attention to relevant stimuli (Miller and Beninger 1991). Sensory neglect contralateral to the lesioned side makes the animal turning spontaneously or when disturbed (e.g. by pinching its tail) towards the lesioned side (Ungersted 1971b). Upon administration with prototypical psychostimulants, such as amphetamine or cocaine, the predominant activation of dopamine receptors in the non-denervated striatum induced by a large dopamine release significantly increases the interest of the animal for stimuli coming from the lesioned side, leading to strong ipsilateral turning. On the other hand, low doses of direct dopamine receptor agonists leads to a predominant activation in the striatum ipsilateral to the lesion, which is dependent on a dopamine denervation-induced up-regulation (increased density or functional response) of dopamine D1 and D2 receptors (Creese et al. 1977; Neve et al. 1984; Gerfen 2002). This increases the interest of the animal for stimuli coming from the non-lesioned side, to contralateral turning (Ungerstedt 1971b,c; Ljungberg and Ungerstedt 1976). Pharmacologically, the up-regulation of dopamine receptors in the denervated compared to the ipsilateral striatum is demonstrated by the substantial increase in the potency of direct dopamine receptor agonists at inducing contralateral turning and by the elicitation of the same qualitative rotational behavior when intracranially administered in the striatum ipsilateral to the 6-OHDA lesion (Herrera-Marschitz et al. 1985). In summary, direct and indirect dopamine receptor agonists reproduce or potentiate, respectively, the effect of endogenous dopamine on increasing responsiveness to salient stimuli with orienting and approaching behavior.

After ascertaining the concept of psychomotor activity, Wise and Bozarth (1987) emphasized the evidence of psychomotor activating effects for all known addictive drugs, including those generally considered as central nervous system depressants, such as opiates, alcohol, barbiturates and cannabinoids. The next move was to regard positive reinforcement as a main mechanism involved in drug dependence and then they postulated that psychomotor activating and reinforcing effects of all addictive drugs share a common mechanism, activation of ascending dopamine systems. The crux of the theory was that the reinforcing effects of drugs, and thus their addiction liability, could be predicted from their ability to induce psychomotor activation (Wise and Bozarth 1987). A large amount of experimental data has accumulated since the formulation of the psychomotor stimulant theory of addiction about the function of dopamine and the ascending dopamine system. The work by Wolfgang Schultz has been of particular significance. He demonstrated that mesencephalic dopamine cells are particularly involved in the processing of a particular kind of salient stimuli: rewarding stimuli and reward-associated stimuli. Basically two different temporal operating modes of dopamine neuronal function have been described. First, a fast, millisecond-scale, phasic response, which codes for a reward prediction error (Schultz 2002), which therefore provides a rapid response to reward-related signals and can significantly contribute to the role of dopamine in reinforcement. Second, a prolonged, minute-scale, tonic dopamine modulation (Schultz 2002), which provides signals of proximity and value of distant rewards (Howe et al. 2013) and therefore can significantly contribute to the role of dopamine in reward-oriented behaviors.

Dopamine is then particularly involved with increasing responsiveness to rewarding stimuli, with orienting and approaching responses to those stimuli, with reward-oriented behavior. But, concomitantly, dopamine is directly involved in reinforcement, in the learning (“stamping-in”) of stimulus-reward and reward-response associations that follows the receipt of reward (Wise 2004). The reinforcement of stimulus-reward associations establishes signals that guide, orient, to rewards (discriminative stimulus) or that become rewards themselves (conditioned rewarding stimulus). The stamping-in of reward-response associations promotes the learning of the optimal sequential response, the action skill that leads to the reward. The insightful model of basal ganglia function developed by Kim and Hikosaka (2015), based on their elegant experiments on gaze orienting and learning of sequential motor responses in non-human primates, highlights the simultaneous processing of reward-oriented behaviors and reinforcement by all striatal areas. The model also implies that, in support of the psychomotor stimulant theory of addiction, all dopamine-dependent functions (reward-oriented behavior and learning of stimulus-reward and reward-response associations) are simultaneously processed in all striatal areas. In relation to reinforcement, rostral areas are predominantly involved in an initial, more controlled, “volitional” (contingent on the outcome) and accurate and more labile learning, while caudal areas are involved in a slower and more “automatic” (non-contingent on the outcome) and long-lasting learning (Kim and Hikosaka 2015). The same functional dichotomy has been demonstrated in the rodent striatum, but with a medial-lateral distribution, with medial and lateral striatum being preferentially involved with outcome-dependent and habitual learning, respectively (Yin and Knowlton 2006). Both in primates and rodents, this functional striatal heterogeneity fits very nicely with a differential cortical glutamatergic and mesencephalic dopamine innervation (Voorn et al. 2004; Ikemoto 2010; Kim and Hikosaka 2015). In summary, our actual knowledge about the functions of dopamine in the striatum underscores this subcortical structure as being particularly involved in the psychomotor activating and reinforcing effects of psychostimulants.

However, an increasing number of experimental data also indicates that mesencephalic dopamine cells also process aversive stimuli (for recent review, see Holly and Miczek 2016). Electrophysiological experiments have found evidence for the existence of two separated populations of dopamine neurons that respond differently to aversive stimuli. Most dopamine cells respond by decreasing their activity and these are cells that also increase their firing upon presentation of rewarding stimuli or with the termination of an aversive stimulus (Brooks and Berns, 2013; Abraham et al., 2014). The other subpopulation increases its activity upon presentation of an aversive stimulus and it seems to be specifically localized in the most medial and posterior part of the ventral tegmental area (pmVTA; Brooks and Berns 2013; Abraham et al. 2014; Lammel et al. 2014). In fact, this area projects to a specific striatal area, also the posteriomedial part of the shell of the nucleus accumbens (pmNAc shell; Vertes 2004; Quiroz et al. 2015), specifically involved in threat-related behaviors (Richard et al. 2013). The infralimbic cortex innervates both pmVTA and pmNAc shell as well as the amygdala and this circuit plays a key role in “fear” extinction, in the suppression of threat conditioning (Vidal-Gonzalez et al. 2006; Knapska et al. 2012). Importantly, according to Moscarello and LeDoux (2013), active avoidance learning, with the elicitation of a behavioral response that avoids the interaction with the aversive stimulus, requires the suppression of threat conditioning. Then, dopamine is not only associated to positive, but also negative reinforcement. In summary, dopamine promotes approach by directly increasing the responsiveness to reward-related stimuli, but also indirectly by decreasing the withdrawal reaction from previously conditioned aversive stimuli. This indirect mechanism could then be involved in the insensitivity to the aversive stimuli in subjects with SUD (McCutcheon et al. 2012). In fact, in some experimental models of SUD the animal continues to respond for the drug even if they must endure a foot shock that otherwise would be aversive (Deroche-Gamonet et al., 2004).

Psychomotor activating effects of caffeine: The striatal adenosine A2A-dopamine D2 receptor heteromer

Unexpected findings about caffeine were observed when Ungerstedt’s model became established as a reliable method to elucidate the direct or indirect characteristics of a putative dopamine receptor agonist. Caffeine (and theophylline) potentiated the contralateral turning behavior (in rats with unilateral 6-OHDA lesion of the ascending dopamine system) induced by direct dopamine receptor agonists and elicited contralateral turning when administered on its own (Fuxe and Ungerstedt 1974). Since it was soon realized that caffeine did not bind to dopamine receptors, a series of studies followed trying to find the dopamine receptor agonist-like mechanism involved. The intensity of contralateral turning induced by caffeine significantly correlated with that induced by the direct non-selective dopamine receptor agonist apomorphine and was counteracted by dopamine receptor antagonists (Herrera-Marschitz et al. 1988; Casas et al. 1989; Garrett and Holtzman 1995a). More specifically, D2 but not D1 receptor antagonists counteracted caffeine-induced turning behavior (Garrett and Holtzman 1995a). Differently from apomorphine these psychomotor activating effects of caffeine seemed to be totally dependent on the up-regulation of dopamine receptors caused by the striatal dopamine denervation. Thus, apomorphine but not caffeine produced ipsilateral rotational behavior in rats with unilateral striatal kainic acid lesions (Herrera-Marschitz et al. 1988). The dependence on dopamine receptor up-regulation was also demonstrated for the ability of caffeine to counteract dopamine depletion-induced psychomotor depression in reserpinized mice. Systemic administration of reserpine produces catecholamine depletion. This translates into complete akinesia than can be reversed by direct dopamine receptor agonists, either after short- or long-term reserpinization (about 4 or 24 h after reserpine administration, respectively; Starr et al. 1987; Ferré et al. 1991a,b; Giménez-Llort et al. 1995). The same as with dopamine denervation, long-term reserpinization is associated with up-regulation of dopamine receptors with increased sensitivity to the psychomotor activating effects of direct dopamine receptor agonists (Burt et al. 1977). Caffeine and related xanthines produce significant locomotor activity in long- but not short-term reserpinized animals (Ferré et al. 1991b; Giménez-Llort et al. 1995; Shiozaki et al. 1999).

Previous sensitization with direct dopamine receptor agonists was found to be essential in order to observe a contralateral behavior induced by caffeine (Fenu and Morelli, 1998). Thus, classically, apomorphine was always repeatedly administered to demonstrate the existence of a significant unilateral 6-OHDA lesion, leading to a progressive and significant increase in apomorphine-induced contralateral turning (Ungerstedt 1971c, Herrera-Marschitz et al. 1985; Pollack et al. 1997; Fenu and Morelli 1998). Hence, unless previous sensitization of a direct dopamine receptor has been established, caffeine behaves as an indirect dopamine receptor agonist and tends to produce ipsilateral turning (Fenu and Morelli 1998; Cauli et al. 2003). The other way around, repeated but intermittent (non-daily) systemic caffeine administration, a schedule that is not associated with tolerance to its psychostimulant effects, sensitizes the rat to the contralateral and ipsilateral turning induced by direct and indirect dopamine receptor agonists, respectively (Cauli et al. 2003, 2005; Pollack et al. 2010).

Sensitization to direct or indirect dopamine receptor agonists in naïve, non-denervated animals is a well recognized phenomenon that consists of a progressive increase in their psychomotor activating effects that are strongly dependent on the environment in which the drug is administered. The phenomenon extends to all addictive drugs, with their dependence on dopaminergic mechanisms, and it has been suggested to be involved in the development of drug addiction (Kalivas and Steward 1991; Robinson et al. 1998). Again, non-tolerance-associated continuous caffeine exposure (low caffeine concentration in the drinking water) or repeated intermittent caffeine administration induces environment-dependent sensitization to its psychomotor effects and cross-sensitization to direct and indirect dopamine receptor agonists, such as amphetamine (Gasior et al. 2000; Cauli and Morelli 2002; Simola et al. 2006; Zancheta et al. 2012). On the other hand, strong tolerance develops to the psychostimulant effects of caffeine (including turning behavior in rats with a unilateral 6-OHDA lesion) upon continuous caffeine exposure (high caffeine concentration in the drinking water) or repeated daily (systemic) caffeine administration (Holtzman and Finn 1988; Garrett and Holtzman, 1995b; Howell et al. 1997; Karcz-Kubicha et al. 2003; Quarta et al. 2004a). Nevertheless, both sensitization and tolerance to the psychomotor effects of caffeine are independent processes and therefore dependent on different mechanisms. In fact, a washout period of several days after a tolerance-associated continuous or repeated caffeine treatment discloses an apparently latent caffeine sensitization (Hsu et al. 2009, 2010). As mentioned below, caffeine sensitization is A2A receptor-mediated and preferentially involves long-lasting postsynaptic changes, including increased phosphorylation of the cAMP-regulated phosphoprotein of molecular weight 32 kDA (DARPP-32; Hsu et al. 2009). On the other hand, tolerance depends mostly on presynaptic A1 receptor-mediated mechanisms (see below). Altogether, caffeine demonstrates unique pharmacological properties as compared with other psychostimulants: It induces psychomotor activation which qualitatively resembles that of direct or indirect dopamine receptor agonists depending on the experimental conditions; dopamine denervation and previous sensitization with direct dopamine receptor agonists discloses and intensifies the apparent direct dopamine receptor agonistic properties of caffeine.

The enigmatic psychomotor activating effects of caffeine provided one of the main initial findings that would lead to the field of G protein-coupled receptor heteromers (Ferré et al. 2009, 2014). More specifically, it led to the discovery of adenosine-dopamine receptor heteromers (Ferré et al., 1997, 2007). And even more specifically, it led to the establishment of A2A-D2 receptor heteromers as mainly responsible for the psychostimulant effects of caffeine (Ferré et al. 2015). The first evidence came from experiments in short-term reserpinized mice showing differences in the counteracting effects of adenosine receptor agonists on D2 receptor agonist-induced locomotor activation. The order of potency of the adenosine receptor agonists indicated a selective antagonistic interaction between A2A and D2 receptors (Ferré et al. 1991a). Furthermore the effects of A2A receptor activation were dose-dependently counteracted by caffeine and related methylxanthines (Ferré et al. 1991b).

With the availability of selective A2A receptor ligands, a large number of experiments demonstrated that A2A receptor agonists and antagonists induce the same qualitative psychomotor depressant and activating effects that D2 receptor antagonists and agonists, respectively; (Ferré et al. 1991c; Kanda et al. 1994; Rimondini et al. 1997; Shiozaki et al. 1999; Randall et al. 2011; Nunes et al. 2013); that A2A receptor agonists and antagonists selectively counteract and potentiate the psychomotor activating effects of D2 receptor agonists, respectively (Popoli et al. 1996; Rimondini et al. 1998; Stromberg et al. 2000; Ferré et al. 2001); but also, that selective A2A, but not A1, receptor antagonists counteract the psychomotor depressant effects of reserpine and D2 receptor antagonists (Kanda et al. 1994; Shiozaki et al. 1999; Pardo et al. 2012; Nunes et al. 2013; Minor and Hanff 2015). Initial studies dealt mostly with locomotor activity recording, but more recent studies about the psychomotor activating effects of caffeine also dealt with measures of specific reward-oriented behavior, with caffeine and A2A receptor antagonists increasing the responsiveness to specific rewarding stimuli, such as those associated with regular food (Randall et al. 2011; Nunes et al. 2013), sucrose solutions (Brianna Sheppard et al. 2012) and those eliciting maternal behavior (Pereira et al. 2011) and intracranial self-stimulation (Lazenka et al. 2015). Lastly, A2A but not A1 receptor antagonists induce sensitization to their psychomotor-activating effects and cross-sensitization to caffeine (Hsu et al. 2009, 2010).

A2A and D2 receptors were found particularly expressed in the striatum and co-localized in the same neuron, the GABAergic striato-pallidal neuron (Schiffmann et al. 1991; Ferré et al. 1991d). Together with the GABAergic striato-nigral neuron, they constitute more than ninety percent of the entire neuronal population. We have now a large amount of experimental evidence for the existence of a predominant striatal population of both A2A and D2 receptors forming functionally and pharmacologically significant heteromers that modulate the function of the GABAergic striato-pallidal neurons (Ferré et al. 1993; Azdad et al. 2009; Bonaventura et al. 2015; Ferré et al. 2015). This predominant population of specific subtypes of adenosine and dopamine receptors localized in one of the two predominant populations of striatal neurons provides a frame for the apparent preferential role of A2A and D2 receptors in the psychostimulant effects of caffeine. Recent studies suggest that A2A-D2 receptor heteromers constitute a heterotetrameric structure with A2A and D2 receptor homodimers coupled to their cognate Gs/olf and Gi/o protein, respectively (Bonaventura et al. 2015; Ferré 2015). The heterotetrameric structure allows multiple simultaneous and reciprocal interactions between adenosine and dopamine and exogenous A2A and D2 receptor ligands (Navarro et al. 2014; Bonaventura et al. 2015; Ferré et al. 2015). The two most salient interactions are the ability of adenosine or exogenous A2A receptor ligands to decrease the affinity and intrinsic efficacy of dopamine or exogenous D2 receptor ligands (allosteric A2A-D2 interaction) and the ability of D2 receptor agonist-mediated and Gi/o protein-dependent counteraction of A2A receptor agonist-mediated and Gs/olf-dependent activation of adenylyl-cyclase (adenylyl-cyclase A2A-D2 interaction). In fact, it can be postulated that the canonical Gs-Gi interaction at the adenylyl-cyclase level depends on heteromerization of Gs- and Gi-coupled homodimers (Guitart et al. 2014; Navarro et al. 2014; Ferré 2015). The A2A-D2 receptor heteromer acts as an integrative device that allows very elaborated interactions between adenosine and dopamine controlling the function of the GABAergic striato-pallidal neuron: preferential A2A versus D2 receptor activation leads to an increased neuronal activity by activating adenylyl-cyclase and by allosterically counteracting D2 receptor signaling; preferential D2 versus A2A receptor activation leads to a decreased neuronal activity by G protein-dependent and independent mechanisms and by counteracting A2A receptor-mediated activation of adenylyl-cyclase (Navarro et al. 2014; Bonaventura et al. 2015, Ferré et al. 2015). Increases or decreases in the activity of the GABAergic striato-pallidal neuron leads to the opposite, decreases and increases in psychomotor activity, respectively. Thus, a pathogenic hallmark of akinesia in Parkinson’s disease is a pronounced hyperactivity of the GABAergic striato-pallidal neuron. This is in fact the rational for our originally suggested (Ferré et al. 1992) and recently implemented use of A2A receptor antagonists in this disease (Muller and Ferré 2007; Morelli et al. 2009; Armentero et al. 2011).

Under resting physiological conditions there is a tonic activation of A2A and D2 receptors by the endogenous neurotransmitters with a final integration resulting in predominant A2A versus D2 receptor signaling and a predominant allosteric A2A-D2 receptor interaction (Fig. 1A), leading to low psychomotor activity. In the presence of rewarding-related stimuli, striatal dopamine release leads to a predominant D2 versus A2A receptor signaling, now with a predominant adenylyl-cyclase A2A-D2 receptor interaction (Fig. 1B), leading to psychomotor activation. Maybe not surprisingly if we consider A2A and D2 receptors as one functional receptor unit, dopamine depletion by reserpine, 6-OHDA lesion or genetic engineering leads to a prominent up-regulation (increased density or functional response) of both D2 and A2A receptors (Burt et al. 1977; Creese et al. 1977; Neve et al. 1984; Ferré and Fuxe 1992; Pinna et al. 2002; Bhattacharjee et al. 2011). In fact, both receptors have been found to be up-regulated in patients with Parkinson’s disease (Antonini et al. 1995; Ichise et al. 1999; Hurley et al. 2000; Calon et al. 2004; Varani et al. 2010). Then, the model that considers A2A and D2 receptor signaling, their interactions and their dopamine depletion-dependent up-regulation in the frame of the A2A-D2 receptor heteromer can explain the psychomotor activating effects of caffeine. Based on experimental findings from dopamine depleted animals, the model assumes that adenosine plays a much more important role than previously suspected. Up-regulation of D2 receptors can compensate for the small but still functional concentration of extracellular dopamine, but up-regulation of A2A receptors increases the effect of endogenous adenosine and shifts the balance between A2A and D2 receptor signaling even further in favor to A2A, leading to pronounced neglect of rewarding stimuli, to psychomotor depression (Fig. 1C). Under these conditions, either a D2 receptor agonist (Fig. 1D) or caffeine or a selective A2A receptor antagonist (Fig. 1E) change the balance to a predominant D2 receptor signaling, leading to increased responsiveness to rewarding stimuli, to psychomotor activation. Without dopamine depletion, without up-regulation of A2A or D2 receptors, caffeine or a selective A2A receptor antagonist produces a less pronounced imbalance in favor of dopamine by blocking less potently A2A receptors, but still being able to produce an increase in psychomotor activity (Fig. 1F). As shown in Fig. 2, the model can explain the rotational behavior in rats with unilateral striatal dopamine denervation, not only the ipsilateral and contralateral turning to the lesion side induced by indirect and direct dopamine receptor agonists, respectively, but also the contralateral turning induced by caffeine (see figure legend for details). The model, which implies a significant “active” role of adenosine on the depressant psychomotor effects produced by dopamine depletion, a situation of bilateral dopamine denervated striata (Fig. 1C), can also explain the ability of caffeine to reverse the adipsic-aphagic syndrome in bilateral 6-OHDA-lesioned rats (Casas et al. 2000) and in genetically induced dopamine-deficient mice (Kim and Palmiter 2003, Palmiter 2008) (Fig. 1E). In these mice, in fact, a selective A2A but not an A1 receptor antagonist induced feeding and locomotion (Kim and Palmiter 2003).

Figure 1
Model of the striatal A2A-D2 receptor heteromer as a main mechanism for the psychomotor and reinforcing effects of psychostimulants
Figure 2
Model of the striatal A2A-D2 receptor heteromer as a main mechanism for the rotational behavior in unilateral 6-OHDA-lesioned rats induced by direct and indirect dopamine receptor agonists and by caffeine

In summary, the accumulated knowledge about the function of the striatal A2A-D2 receptor heteromer demonstrates that it is a main target for the psychomotor activating effects of caffeine. However, this is still an incomplete picture. Caffeine also increases dopamine neurotransmission by additional mechanisms related to blockade of striatal presynaptic A1 receptors that modulate dopamine and glutamate release (Quarta el al. 2004b; Ciruela et al. 2006) and postsynaptic A1 receptors that form heteromers with D1 receptors in the GABAergic striato-nigral neuron (Ferré et al. 1997; Ferré, 2008). A series of experiments performed in the laboratory of Steven Goldberg demonstrated the involvement of A1 receptors in the acute psychomotor activating (locomotor activity), discriminative-stimulus and dopamine-releasing effects of caffeine (Solinas et al. 2002, 2005; Karcz-Kubicha et al. 2003; Quarta et al. 2004a,b; Antoniou et al. 2005; Borycz et al. 2007). Nevertheless, tolerance developed to the effects of A1 receptor blockade upon continuous caffeine exposure in the drinking water, while its residual locomotor activating effects depended mostly on A2A receptor blockade (Karcz-Kubicha et al. 2003; Quarta et al. 2004a). In the same line of research, it was shown that upon repeated and frequent (twice daily) treatment, tolerance did not develop to the locomotor effects of an A2A antagonist (Halldner et al. 2004). Importantly for the therapeutic implications for Parkinson’s disease, tolerance did not develop either to the potentiating effects of A2A receptor antagonists on the psychomotor activating effects (turning behavior) of D2 receptor agonists or L-dopa (Popoli et al. 2000; Pinna et al. 2001). The precise mechanisms for caffeine-tolerance are not yet fully elucidated, but involve several pharmacokinetic and pharmacodynamic variables that include increase in plasma adenosine levels (Conlay et al. 1997) and up-regulation with increased density or functional response of A1 receptors (Jacobson et al. 1996; Karcz-Kubicha et al. 2003). This seemingly compensatory changes lead to an increased adenosine tone, which is well manifested upon withdrawal. Thus, withdrawal from chronic treatment with caffeine leads to a significant reduction of spontaneous psychomotor activity (measured as spontaneous locomotion) and a reduction of adenosine receptor agonist-induced psychomotor depression (Nikodijevic et al. 1993).

A1 receptor also plays a role in the arousing effects of caffeine, which can be dissociated from the other psychostimulant effects in terms of the underlying mechanism, since they are mostly independent of the activity of the ascending dopamine systems (reviewed in Ferré 2010). Adenosine is a main mediator of sleepiness following prolonged wakefulness, when it accumulates in the extracellular space of the basal forebrain, cortex and hypothalamus (Porkka-Heiskanen et al. 2000; Basheer et al. 2004; McCarley 2007). This accumulation depends on ATP released from astrocytes and converted to adenosine in the extracellular space (Hines and Haydon 2014), which leads to: A1 receptor-mediated inhibition of the cells of origin of the corticopetal basal forebrain system (Basheer et al. 2004; McCarley 2007); inhibition of corticofugal neurons from prefrontal cortex that target the origin of pontine ascending arousal systems (Van Dort et al. 2009), also mediated by A1 receptors; and inhibition of hypothalamic histaminergic and orexinergic ascending arousal systems, with both A1 and A2A receptors being involved (Huang et al. 2005; McCarley 2007; Szymusiak and McGinty 2008; Lazarus et al. 2011). By disinhibiting adenosine-mediated inhibition of the ascending arousal systems, caffeine also increases the responsiveness to non-rewarding salient stimuli.

Reinforcing effects of Caffeine and the DSM-5

As reviewed so far, the same as prototypical psychostimulants (cocaine, amphetamine), caffeine has arousing and psychomotor activating effects, which depend on its ability to disinhibit the brake that endogenous adenosine imposes on the ascending arousal and dopamine systems, respectively. According to the psychomotor stimulant theory of addiction, its psychomotor activating effects predict reinforcing effects and addiction liability. In fact, acute caffeine administration induces as much or even more pronounced psychomotor activity than opiates, nicotine, THC, barbiturates or alcohol, all well-established substances with reinforcing and addictive properties. Reinforcing effects of caffeine can be demonstrated in the experimental animal and humans. However, as discussed below, both in humans and in the experimental animal, caffeine demonstrates weaker reinforcing effects as compared to prototypic psychostimulants and other common addictive substances. Nevertheless, in drug-discrimination studies in users of prototypical psychostimulants, low to intermediate doses of caffeine produce a profile of positive subjective effects similar to those of amphetamine and cocaine, while with high doses of caffeine the subjects report aversive subjective feelings of anxiety and nervousness (Garrett and Griffths 1997).

In the experimental animal, caffeine-induced learning of stimulus-reward associations has been well documented, although there are no conclusive results about learning of reward-response associations. Thus, the experimental animal develops taste preference for flavors associated with caffeine (Brockwell et al. 1991; Fedorchak et al. 2002; Myers and Izbicki 2006), but maintains caffeine self-administration under a limited range of conditions (Griffiths and Woodson 1988). Low and high doses of caffeine, in the psychomotor activating range, produce taste and place preference and aversion, respectively (Steigerwald et al. 1988; Brockwell et al. 1991; Myers and Izbicki 2006). Previous caffeine consumption allows adaptation to the aversive effects and facilitates taste preference with high doses (Myers and Izbicki, 2006). Similarly, humans also develop taste preference with caffeine, but a consistent finding is that they do not develop preference for a caffeine-paired flavor unless they are at least moderate daily caffeine consumers and unless flavor-caffeine pairing occurs after abstinence long enough to produce withdrawal symptoms (Yeomans et al. 1998; Chambers et al. 2007). Indeed, the American Psychiatry Association (2013) has just accepted ‘caffeine withdrawal’ as a clinical diagnosis. Its symptoms include headache, marked fatigue or drowsiness, dysphoric or depressed mood or irritability, difficulty concentrating, and flu-like symptoms. Negative reinforcement seems therefore to play an additional role in caffeine use (Garrett and Griffiths 1998; Yeomans et al. 1998; James and Rogers 2005; James and Keane 2007). Nevertheless, a recent study showed that caffeine produces significant taste preference regardless of usual caffeine intake (Panek et al. 2013), without implying ‘withdrawal reversal’ (see below).

Following recommendation from Hasin et al. (2013), the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5; American Psychiatric Association 2013) combined the DSM-4 categories of ‘Substance Abuse’ and ‘Substance Dependence’ into a single disorder, ‘Substance Use Disorder’ (SUD), which is measured on a continuum from mild to severe. Each specific substance (except for caffeine) is addressed as a separate disorder (e.g., alcohol use disorder, cocaine use disorder, etc.), but nearly all substances are diagnosed based on the same criteria. Drug craving is added to the list and problems with law enforcement are eliminated because of cultural considerations. For the diagnosis, individuals must fulfill at least two of the following criteria: 1) substance used in lager amounts or over longer periods than intended; 2) a persistent desire or unsuccessful effort to control use; 3) a great deal of time spent obtaining, using or recovering from the substance; 4) craving the substance; 5) substance use interfering with ability to fulfill major obligations; 6) substance use despite social problems related to use; 7) important occupational or social activities given up because of substance use; 8) recurrent use in situations when it is physically hazardous; 9) substance use despite harm; 10) tolerance; 11) withdrawal. The DSM-5 suggests using the number of criteria met as a general measure of severity, from mild (two–three criteria) to moderate (four–five criteria) and severe (six or more criteria).

DSM-5 does not include a diagnosis of ‘caffeine use disorder’, although it is included in section III: conditions for further study, “to stimulate research that will determine the reliability, validity and prevalence of caffeine use disorder based on the proposed new established diagnostic schema”. The proposed diagnostic schema proposed for caffeine use disorder differs from all other SUDs and requires the presence of at least criteria 2, 9 and 11 mentioned above. According to the DSM-5, this higher threshold is intended to prevent over-diagnosis of caffeine use disorder given the prevalence of non-problematic caffeine use in the general population (American Psychiatric Association 2013). Even though there is a substantial amount of studies and reports indicating that a subset of caffeine users develops clinically significant symptoms severe enough to seek treatment (Juliano et al., 2012; Budney et al. 2015), there is no agreement about the real health danger upon caffeine regular consumption (Addicott 2014). The difficulties in accepting caffeine use disorder parallels the preclinical evidence for the relatively mild reinforcing effects of caffeine as compared to those of prototypical psychostimulants.

The differences between the efficacy of caffeine at inducing psychomotor activation, reinforcing effects and putatively SUD, as compared with other drugs, can be attributed to several factors coming from both sides. On one side, caffeine does not produce such a strong dopamine activation as that produced by prototypical psychostimulants. Furthermore, caffeine is aversive at doses that otherwise could potentially promote abuse. On the other side, although caffeine produces locomotor activation than alcohol, THC, barbiturates and opioids, these addictive drugs have depressant effects that depend on different mechanisms and can mask their potential locomotor activating effects. This interpretation is particularly supported by recent studies on interactions between caffeine and alcohol (see below). We can assume than drug-induced activation of striatal dopamine receptors implies reinforcing effects, but not automatically SUD liability. Self-administration in animals and SUD in humans depend on a strong and fast activation of dopaminergic neurotransmission (Volkow et al., 2011). Prototypical psychostimulants such as amphetamine or cocaine, as well as cathinones, the emerging family of synthetic chemicals found under the marketed term “bath salts” (Lehner and Baumnann 2013), produce their powerful pharmacological effects by a presynaptic mechanism, interacting with the dopamine transporter (DAT). This causes a fast and pronounced increase of extracellular dopamine, which leads to a pronounced activation of dopamine receptors. As mentioned before, apart from potentiating the effects of endogenous dopamine by adenosine-dopamine receptor interactions, caffeine also produces dopamine release (Solinas et al. 2002; Quarta et al. 2004a,b). However, this is a relatively small effect as compared to prototypical psychostimulants and it seems to be particularly evident in the most medial and dorsal part of the striatum (Borycz et al. 2007).

Paraxanthine, the main metabolite of caffeine in humans, is also a non-selective adenosine receptor antagonist and it has been recently reported to induce stronger psychomotor activation, measured as locomotion, and striatal dopamine releasing effects than caffeine (Orrú et al. 2013). It was found that part of the pharmacological effects of paraxanthine is adenosine independent (related to selective inhibition of cGMP-preferring phosphodiesterases) and it was suggested that it could indirectly contribute to the reinforcing effects of caffeine (Orrú et al. 2013). Nevertheless, in experiments with intracranial self-stimulation, caffeine but not paraxanthine increased reward-oriented behavior (Lazenka et al. 2015). Cocaine, amphetamine and caffeine increased total, reinforced and non-reinforced responding, but paraxanthine increased only total responses and non-reinforced responses (Lazenka et al. 2015). As discussed by Lazenka et al. (2015), in contrast to their study, caffeine did not facilitate intracranial self-stimulation in previous studies by another research group that used a different procedure (autotitration procedure; Mumford & Holtzman 1990, 1991; Mumford et al. 1988). The limited range of conditions across which caffeine produces a facilitation of intracranial self-stimulation resembles the limited range of conditions across which caffeine maintains self-administration (Griffiths & Woodson 1988) and provides additional evidence for the weak abuse-related effects of caffeine relative to other psychostimulants, such as amphetamine or cocaine. The clear dissociation between paraxanthine-induced locomotor activation and facilitation of reward-oriented behavior is certainly unique, claiming for an additional effect of paraxanthine and maybe caffeine in a lower locomotion integrative center. In fact, it has recently been reported that caffeine stimulates locomotor activity in the rat spinal cord, by a mechanism involving A1-D1 receptor interactions (Acebedo et al. 2016).

We should not leave out one final consideration about the very prevalent consumption of caffeine by humans. Otherwise, it is usually inferred as only related to its dopamine-related psychomotor (reward-oriented behavior) and reinforcing (positive and negative) effects. It is about its potent arousal effects, which depend on the specific ability of caffeine to counteract the effects of endogenous adenosine on the ascending arousal systems (see above). We get into the controversial field of the potential attention- and performance-enhancing properties of caffeine, also dependent on the activity of the ascending arousal systems. This takes us back to the reinforcing effects, to negative reinforcement. First, as mentioned above, strong tolerance develops to the striatal A1 receptor-mediated psychomotor and dopamine-releasing effects of caffeine upon continuous exposure or repeated daily administration (Holtzman and Finn 1988; Garrett and Holtzman 1995b; Howell et al., 1997; Karcz-Kubicha et al. 2003; Quarta et al. 2004a). Now the question is if tolerance also develops to the A1 receptor-mediated arousal effects of caffeine. In fact, in the experimental animal, sleep deprivation promotes the same biochemical changes observed during repeated treatment or continuous exposure with caffeine, increased adenosine levels (see above) and up-regulation of A1 receptors, which correlate with sleepiness (Elmenhorst et al. 2009; Kim et al. 2012). Also, in humans, sleep deprivation has been shown to increase the density of A1 receptors in the prefrontal cortex (Elmenshorst et al. 2007). Thus, these mechanisms must play an important role in the sleepiness, marked fatigue and drowsiness of caffeine withdrawal. Therefore, an important component of the improvement in attention, performance and wakefulness by caffeine in humans could be explained by relieving withdrawal symptoms, by withdrawal reversal (James and Rogers 2005; James and Keane 2007). Nevertheless, the same as for taste preference experiments (Panek et al. 2013), better controlled studies are providing evidence for arousal effects of caffeine that are independent of the withdrawal reversal (Addicott and Laurienti 2009), which would also fit with the preclinical studies indicating an additional role of A2A receptors in the arousal effects of caffeine and the lack of tolerance to A2A receptor-dependent caffeine mechanisms (see above).

The real danger: Caffeine potentiates the addictive and toxic effects of drugs of abuse and could increase vulnerability to SUD

While more clinical research needs to be done to determine if caffeine use disorder can adhere to the general scheme of SUD and about the real contribution of arousal/withdrawal reversal in caffeine use, there is at present no reasonable doubt in the literature about the fact that a rising real societal danger of caffeine is its association with other drugs that fulfill the DSM-5 criteria for SUD. Caffeine is a unique psychostimulant endowed with the capacity to significantly potentiate the effects of prototypical psychostimulants and all other drugs of abuse. Back to the striatal A2A-D2 receptor heteromer model, a prototypical psychostimulant, an indirect dopamine receptor agonist such as amphetamine or cocaine leads to a predominant D2 versus A2A receptor signaling, with a predominant adenylyl-cyclase A2A-D2 receptor interaction, leading to psychomotor activation (Fig. 3B). By blocking the A2A receptor, caffeine counteracts the remaining brake that endogenous adenosine imposes on D2 receptor signaling, which results in a maximal D2 and minimal A2A receptor signaling: a maximal psychostimulant effect (Fig. 3C). Furthermore, presynaptic mechanisms cannot be excluded, such as the recently reported ability of caffeine to potentiate dopamine release induced by the amphetamine derivative 3,4-methylenedioxymethamphetamine, MDMA or “ecstasy” (Górska and Golembiowska 2015).

Figure 3
Model of the striatal A2A-D2 receptor heteromer as a main mechanism for caffeine-induced potentiation of the psychomotor activating and reinforcing effects of prototypical psychostimulants

Acutely, caffeine administration has been shown to dose-dependently augment the psychomotor effects of prototypical psychostimulants, such as cocaine or amphetamine, as measured with locomotor activity (Andén and Jackson 1975; White and Keller 1984; Misra et al. 1986), stereotyped behavior (Klawans et al. 1974) and also reward/drug-oriented behavior (Worley et al. 1994; Schenk et al. 1994, 1996). In this case, the reward is the drug of abuse and the psychomotor effects are measured as an increase in drug self-administration or reinstatement of the extinguished self-administration. Reinstatement (stress-, drug- or context-induced) is commonly used as a measure of drug-seeking behavior. Furthermore, caffeine was shown to partially generalize and to potentiate the discriminative stimulus effects of cocaine, amphetamine or methamphetamine (Schechter 1977; Gauvin et al. 1990; Young et al. 1998; Munzar et al. 2002). Drug-discrimination techniques in rodents and primates have been commonly used to study abuse-related effects by establishing the interoceptive effects of a training drug (e.g., cocaine) as a cue for performing a specific operant response (e.g., lever pressing reinforced by food). During training with this protocol, pressing one lever is reinforced when the training drug is injected before the start of the session, and responding on a second lever is reinforced when vehicle is injected before the session. Lever choice during test sessions can then be used as an indication of whether a drug has effects similar to the training drug (generalization), or whether it modifies the effects of the training drug (Solinas et al. 2006). As expected, the same potentiating effects of caffeine on drug seeking and drug discrimination have been documented for selective A2A receptor antagonists (Justinova et al. 2003; O’Neill et al. 2012).

Significantly, caffeine also potentiates the psychomotor effects of prototypical psychostimulants upon repeated treatment or continuous exposure, which is most probably related to the association of cross-sensitization (see above) with the lack of cross-tolerance (Jain and Holtzman 2005). Thus, repeated treatment or continuous exposure of caffeine has been shown to augment the psychomotor effects of cocaine or amphetamine, as measured with locomotor activity (Schenk et al. 1990; Gassior et al. 2000), turning behavior (Cauli et al. 2003) and reward/drug-oriented behavior (Horger et al. 1991; Jaszyna et al. 1998). Using the drug-discrimination paradigm, Goldberg’s research group also demonstrated that continuous exposure to caffeine is associated with tolerance to the ability of A1 but not A2A receptor antagonists to potentiate the discriminative-stimulus effects of cocaine or amphetamine (Justinova et al. 2009). Lastly, coadministration of caffeine or an A2A receptor antagonist has been shown to potentiate cocaine-induced sensitization of psychomotor activity (Filip et al. 2006; Prieto et al. 2015). Altogether, preclinical data strongly suggest that, acutely or chronically consumed, caffeine potentiates the psychostimulant effects of prototypical psychostimulants.

Apart from coffee, tea and other caffeine containing plant-extracts, caffeine is found in many commercially available products such as energy drinks, which may be consumed with other drugs in recreational drug use settings (Reissig et al. 2009). Another actual threat is the very common use of caffeine as an adulterant in illicit drug preparations (Cole et al. 2011; López-Hill et al. 2011; Seely et al. 2013), particularly with cocaine, amphetamine derivatives and synthetic cathinones (Seely et al. 2013; López-Hill et al. 2011). Caffeine was found to be a major adulterant in coca paste seized samples and demonstrated to significantly potentiate the acute psychomotor effects and sensitization induced by those samples administrered to rats (López-Hill et al. 2011; Prieto et al. 2015). Also unambiguous preclinical data have shown that caffeine not only increases the pharmacological effects but also the toxic effects of prototypical psychostimulants, in particular the acute toxicity of substituted amphetamines, such as MDMA and 3,4-methylenedioxyamphetamine (MDA), manifested as high core body temperature, tachycardia and increased mortality (reviewed in Vanattou-Saifoudine et al. 2012). Also, upon repeated co-administration, caffeine enhances MDMA-induced neuroinflamatory glial reactivity (Khairnar et al. 2010). In summary, although generally thought to be mostly listed as a bulk adulterant (Cole et al. 2011), the overwhelming preclinical evidence for the enhancing psychomotor and toxic effects of other recreational psychostimulants by caffeine calls for the urgent need of control or at least for increasing social awareness.

Caffeine and alcohol constitute another alarming combination with increasing popularity, particularly the association of energy drinks with alcoholic beverages among the adolescent and young adult population (O’Brien et al. 2008; Reissig et al. 2009; Peacock et al. 2014; McKetin et al. 2015). First, energy drinks and caffeine beverages in general facilitate alcohol drinking and related harms by reducing its effects on intoxication. Thus, caffeine attenuates the “unwanted” somnogenic and ataxic effects of alcohol, which depend on its ability to increase the extracellular concentration of adenosine (by direct inhibition of the equilibrative nucleoside transporter ENT1) and activate A1 and A2A receptors that inhibit the ascending arousal systems and A1 receptors localized in the cerebellum and other brain areas. This adenosine increase occurs under conditions of acute alcohol intake (reviewed in Ferré and O’Brien 2011). Second, we recently proposed that, based on mechanisms involving the striatal A2A-D2 receptor heteromer (Fig. 3), caffeine should strongly potentiate the “wanted” effects of alcohol, its psychostimulants effects (Ferré and O’Brien 2011). In fact, recent research suggests that energy drinks combined with alcohol increases the “desire” to drink (Marczinski et al. 2013). It is widely believed that the reinforcing effects of alcohol depend on its ability to produce striatal dopamine release by direct and indirect mechanisms that increase the activity of dopamine neurons (Tupala and Tiihonen 2004; Morikawa and Morrisett 2010). Under conditions of acute alcohol intake, the increased adenosine tone tends to counteract its psychomotor and reinforcing effects, which should then be strongly potentiated by caffeine (Ferré and O’Brien 2011). Recent experiments in mice have provided strong evidence for this hypothesis, showing that combination of caffeine and alcohol produce a stronger locomotor activity than either drug administered alone (Hilbert et al., 2013). The same research group recently reported that when given by oral gavage, repeated co-exposure to alcohol and caffeine produces a much larger effect than repeated exposure to either drug alone (May et al. 2015). Under conditions of chronic alcohol intake (alcohol use disorder), in contrast to the acute situation, there is a reduced adenosine tone. In fact, chronic alcohol exposure results in an increased expression of ENT1 and, therefore, a decrease in alcohol-mediated inhibition of ENT1 (Parkinson et al. 2009). This decrease in the adenosine tone is at least partially responsible for the tolerance to the acute effects of alcohol and also to the main symptoms of alcohol withdrawal, such as insomnia, anxiety, and seizures (Concas et al. 1994; Gatch et al. 1999; Prediger et al. 2006). In fact, a study with human subjects showed that a history of combined alcohol and caffeine administration increases alcohol tolerance compared with a history to either drug alone (Fillmore 2003). In addition, a chronically reduced adenosine tone should potentiate the psychomotor and reinforcing effects of alcohol, its psychostimulants effects. Altogether, the clinical and preclinical data on caffeine- and adenosine-alcohol interactions provide nice support for the psychomotor stimulant theory of addiction, which would predict that counteracting the adenosine-mediated psychomotor depressant (“unwanted”) effects of alcohol by decreasing adenosine (chronic alcohol use) or blocking adenosine receptors (caffeine) should disclose its potentially very strong psychostimulants effects.

A final consideration of the potential social danger of caffeine is its use by children and adolescents. The availability of caffeine in the young population is a source of growing concern (Temple 2009). Reviews in the literature have suggested that children may not be more sensitive than adults to caffeine and that perceived differences are due to lower body weight (Nehlig et al. 1992; Leviton 1992). However, animal models, which offer the possibility of controlled longitudinal studies, are bringing a completely different picture. First, in adolescent rats, the acute psychomotor activating effects of caffeine are stronger and its depressant effects (with higher doses) milder than in adult rats, suggesting than adolescents can consume higher amounts (Marin et al. 2011). Second, after chronic treatment with caffeine, both tolerance to the acute psychomotor activating effects and withdrawal-induced psychomotor depression were significantly more pronounced in adolescent rats, suggesting that adolescents can be more dependent on caffeine (withdrawal reversal) than the adult population (Rhoads et al. 2011). Finally, caffeine consumption by adolescent rats increases the psychomotor activating effects of cocaine in the adult rats (measured with locomotor activity and place preference). Significantly, the behavioral results were associated with up-regulation and down-regulation of striatal D2 and A2A receptors, respectively (O’Neill et al. 2015). This would imply that caffeine use by adolescents could produce long-lasting neurochemical changes in the brain (in adenosine-dopamine neurotransmission) that can increase vulnerability to SUD, as at least supported by a controlled study using an epidemiologic and monozygotic-twin analysis (Kendler et al. 2006).

Conclusion

The knowledge accumulated during the last three decades about the role of the ascending dopamine systems in psychomotor activity and reinforcement, the identification of the ascending arousal systems and their interconnections, the role of adenosine and adenosine receptors in the modulation of ascending dopamine and arousal systems and the discovery of the adenosine-dopamine receptor heteromers, allows us to understand the mechanisms behind the psychostimulant effects of caffeine. We are now able to evaluate more directly, both in humans and the experimental animal, unequivocal main pharmacological targets of caffeine, such as the A2A-D2 receptor heteromer (Bonaventura et al. 2015; Volkow et al. 2015). This should help us determine the real societal values and dangers of such a unique psychostimulant, the most used psychoactive drug in the world.

Acknowledgments

Work supported by the intramural funds of the National Institute on Drug Abuse. The author thanks Dr. Roy A. Wise for his critical review of the manuscript.

References

  • Abraham AD, Neve KA, Lattal KM. Dopamine and extinction: a convergence of theory with fear and reward circuitry. Neurobiol Learn Mem. 2014;108:65–77. [PMC free article] [PubMed]
  • Acevedo J, Santana-Almansa A, Matos-Vergara N, Marrero-Cordero LR, Cabezas-Bou E, Díaz-Ríos M. Caffeine stimulates locomotor activity in the mammalian spinal cord via adenosine A1 receptor-dopamine D1 receptor interaction and PKA-dependent mechanisms. Neuropharmacology. 2016;101:490–505. [PMC free article] [PubMed]
  • Addicott MA. Caffeine Use Disorder: A Review of the Evidence and Future Implications. Curr Addict Rep. 2014;1:186–192. [PMC free article] [PubMed]
  • Addicott MA, Laurienti PJ. A comparison of the effects of caffeine following abstinence and normal caffeine use. Psychopharmacology. 2009;207:423–431. [PMC free article] [PubMed]
  • American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders. (5th) 2013
  • Andén NE, Jackson DM. Locomotor activity stimulation in rats produced by dopamine in the nucleus accumbens: potentiation by caffeine. J Pharm Pharmacol. 27:666–670. (975) [PubMed]
  • Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol. 1995;52:1183–1190. [PubMed]
  • Antoniou K, Papadopoulou-Daifoti Z, Hyphantis T, Papathanasiou G, Bekris E, Marselos M, Panlilio L, Müller CE, Goldberg SR, Ferré S. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology. 2005;183:154–162. [PubMed]
  • Armentero MT, Pinna A, Ferré S, Lanciego JL, Müller CE, Franco R. Past,present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther. 2011;132:280–299. [PMC free article] [PubMed]
  • Azdad K, Gall D, Woods AS, Ledent C, Ferré S, Schiffmann SN. Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology. 2009;34:972–986. [PubMed]
  • Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep-wake regulation. Prog Neurobiol. 2004;73:379–396. [PubMed]
  • Bhattacharjee AK, Lang L, Jacobson O, Shinkre B, Ma Y, Niu G, Trenkle WC, Jacobson KA, Chen X, Kiesewetter DO. Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425. Nucl Med Biol. 2011;38:897–906. [PMC free article] [PubMed]
  • Bonaventura J, Navarro G, Casadó-Anguera V, Azdad K, Rea W, Moreno E, Brugarolas M, Mallol J, Canela EI, Lluís C, Cortés A, Volkow ND, Schiffmann SN, Ferré S, Casadó V. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. Proc Natl Acad Sci USA. 2015;112:E3609–E3618. [PubMed]
  • Borycz J, Pereira MF, Melani A, Rodrigues RJ, Köfalvi A, Panlilio L, Pedata F, Goldberg SR, Cunha RA, Ferré S. Differential glutamate-dependent and glutamate-independent adenosine A1 receptor-mediated modulation of dopamine release in different striatal compartments. J Neurochem. 101:355–363. [PubMed]
  • Brianna Sheppard A, Gross SC, Pavelka SA, Hall MJ, Palmatier MI. Caffeine increases the motivation to obtain non-drug reinforcers in rats. Drug Alcohol Depend. 2012;124:216–222. [PMC free article] [PubMed]
  • Brockwell NT, Eikelboom R, Beninger RJ. Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav. 1991;38:513–517. [PubMed]
  • Brooks AM, Berns GS. Aversive stimuli and loss in the mesocorticolimbic dopamine system. Trends Cogn Sci. 2013;17:281–286. [PubMed]
  • Budney AJ, Lee DC, Juliano LM. Evaluating the Validity of Caffeine Use Disorder. Curr Psychiatry Rep. 2015;17:74. [PubMed]
  • Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977;196:326–328. [PubMed]
  • Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain. 2004;127:1075–1084. [PubMed]
  • Casas M, Ferré S, Cobos A, Grau JM, Jané F. Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway. Neuropharmacology. 1989;28:407–409. [PubMed]
  • Casas M, Prat G, Robledo P, Barbanoj M, Kulisevsky J, Jané F. Methylxanthines reverse the adipsic and aphagic syndrome induced by bilateral 6-hydroxydopaminelesions of the nigrostriatal pathway in rats. Pharmacol Biochem Behav. 2000;66:257–263. [PubMed]
  • Cauli O, Morelli M. Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. Psychopharmacology. 2002;162:246–254. [PubMed]
  • Cauli O, Pinna A, Valentini V, Morelli M. Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology. 2003;28:1752–1759. [PubMed]
  • Cauli O, Pinna A, Morelli M. Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists. Behav Pharmacol. 2005;16:621–626. [PubMed]
  • Chambers L, Mobini S, Yeomans MR. Caffeine deprivation state modulates expression of acquired liking for caffeine-paired flavours. Q J Exp Psychol. 2007;60:1356–1366. [PubMed]
  • Ciruela F, Casadó V, Rodrigues RJ, Luján R, Burgueño J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortés A, Canela EI, López-Giménez JF, Milligan G, Lluis C, Cunha RA, Ferré S, Franco R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci. 2006;26:2080–2087. [PubMed]
  • Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M. Adulterants in illicit drugs: a review of empirical evidence. Drug Test Anal. 2011;3:89–96. [PubMed]
  • Concas A, Cuccheddu T, Floris S, Mascia MP, Biggio G. 2-Chloro-N6-cyclopentyladenosine (CCPA), an adenosine A1 receptor agonist, suppresses ethanol withdrawal syndrome in rats. Alcohol Alcohol. 1994;29:261–264. [PubMed]
  • Conlay LA, Conant JA, deBros F, Wurtman R. Caffeine alters plasma adenosine levels. Nature. 1997;389:136. [PubMed]
  • Creese I, Burt DR, Snyder SH. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science. 1977;197:596–598. [PubMed]
  • Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addiction-like behavior in the rat. Science. 2004;305:1014–1017. [PubMed]
  • Dutertre S, Becker CM, Betz H. Inhibitory glycine receptors: an update. J Biol Chem. 2012;287:40216–40223. [PMC free article] [PubMed]
  • Elmenhorst D, Meyer PT, Winz OH, Matusch A, Ermert J, Coenen HH, Basheer R, Haas HL, Zilles K, Bauer A. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci. 2007;27:2410–2415. [PubMed]
  • Elmenhorst D, Basheer R, McCarley RW, Bauer A. Sleep deprivation increases A(1) adenosine receptor density in the rat brain. Brain Res. 2009;1258:53–58. [PMC free article] [PubMed]
  • Fedorchak PM, Mesita J, Plater SA, Brougham K. Caffeine-reinforced conditioned flavor preferences in rats. Behav Neurosci. 2002;116:334–346. [PubMed]
  • Fenu S, Morelli M. Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors. Eur J Neurosci. 1998;10:1878–1884. [PubMed]
  • Ferré S, Herrera-Marschitz M, Grabowska-Andén M, Ungerstedt U, Casas M, Andén NE. Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice. Eur J Pharmacol. 1991a;192:25–30. [PubMed]
  • Ferré S, Herrera-Marschitz M, Grabowska-Andén M, Casas M, Ungerstedt U, Andén NE. Postsynaptic dopamine/adenosine interaction: II. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice. Eur J Pharmacol. 1991b;192:31–37. [PubMed]
  • Ferré S, Rubio A, Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett. 1991c;130:162–164. [PubMed]
  • Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 1991d;88:7238–7241. [PubMed]
  • Ferré S, Fuxe K, von Euler G, Johansson B, Fredholm BB. Adenosine-dopamine interactions in the brain. Neuroscience. 1992;51:501–512. [PubMed]
  • Ferré S, Fuxe K. Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res. 1992;594:124–130. [PubMed]
  • Ferré S, O'Connor WT, Fuxe K, Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci. 1993;13:5402–5406. [PubMed]
  • Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 1997;20:482–487. [PubMed]
  • Ferré S, Popoli P, Giménez-Llort L, Rimondini R, Müller CE, Strömberg I, Ögren SO, Fuxe K. Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonism Relat Disord. 2001;7:235–241. [PubMed]
  • Ferré S, Ciruela F, Woods AS, Lluis C, Franco R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci. 2007;30:440–446. [PubMed]
  • Ferré S. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem. 2008;105:1067–1079. [PubMed]
  • Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pfleger KD, Pin JP, Volkow ND, Waldhoer M, Woods AS, Franco R. Building a new conceptual framework for receptor heteromers. Nat Chem Biol. 2009;5:131–134. [PMC free article] [PubMed]
  • Ferré S. Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis. 2010;20(Suppl 1):S35–S49. [PubMed]
  • Ferré S, O'Brien MC. Alcohol and Caffeine: The Perfect Storm. J Caffeine Res. 2011;1:153–162. [PMC free article] [PubMed]
  • Ferré S, Casadó V, Devi LA, Filizola M, Jockers R, Lohse MJ, Milligan G, Pin JP, Guitart X. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev. 2014;66:413–434. [PubMed]
  • Ferré S. The GPCR heterotetramer: challenging classical pharmacology. Trends Pharmacol Sci. 2015;36:145–152. [PMC free article] [PubMed]
  • Ferré S, Bonaventura J, Tomasi D, Navarro G, Moreno E, Cortés A, Lluís C,Casadó V, Volkow ND. Allosteric mechanisms within the adenosine A(2A)-dopamine D(2) receptor heterotetramer. Neuropharmacology. 2015 [PubMed]
  • Filip M, Frankowska M, Zaniewska M, Przegaliński E, Muller CE, Agnati L, Franco R, Roberts DC, Fuxe K. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 2006;1077:67–80. [PubMed]
  • Fillmore MT. Alcohol tolerance in humans is enhanced by prior caffeine antagonism of alcohol-induced impairment. Exp Clin Psychopharmacol. 2003;11:9–17. [PubMed]
  • Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2005;105:110–113. [PubMed]
  • Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51:83–133. [PubMed]
  • Fuxe K, Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists. Med Biol. 1974;52:48–54. [PubMed]
  • Garrett BE, Griffiths RR. The role of dopamine in the behavioral effects of caffeine in animals and humans. Pharmacol Biochem Behav. 1997;57:533–541. [PubMed]
  • Garrett BE, Holtzman SG. Does adenosine receptor blockade mediate caffeine-induced rotational behavior? J Pharmacol Exp Ther. 1995a;274:207–214. [PubMed]
  • Garrett BE, Holtzman SG. The effects of dopamine agonists on rotational behavior in non-tolerant and caffeine-tolerant rats. Behav Pharmacol. 1995b;6:843–851. [PubMed]
  • Gasior M, Jaszyna M, Peters J, Goldberg SR. Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J Pharmacol Exp Ther. 2000;295:1101–1111. [PubMed]
  • Gatch MB, Wallis CJ, Lal H. The effects of adenosine ligands R-PIA and CPT on ethanol withdrawal. Alcohol. 1999;19:9–14. [PubMed]
  • Gauvin DV, Criado JR, Moore KR, Holloway FA. Potentiation of cocaine's discriminative effects by caffeine: a time-effect analysis. Pharmacol Biochem Behav. 1990;36:195–197. [PubMed]
  • Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci. 2002;22:5042–5054. [PubMed]
  • Giménez-Llort L, Martínez E, Ferré S. Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-D-aspartate on motor activity in mice. Eur J Pharmacol. 1995;275:171–177. [PubMed]
  • Glickman SE, Schiff BB. A biological theory of reinforcement. Psychol Rev. 1967;74:81–109. [PubMed]
  • Górska AM, Gołembiowska K. The role of adenosine A1 and A2A receptors in the caffeine effect on MDMA-induced DA and 5-HT release in the mouse striatum. Neurotox Res. 2015;27:229–245. [PMC free article] [PubMed]
  • Griffiths RR, Woodson PP. Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav. 1988;29:419–427. [PubMed]
  • Guitart X, Navarro G, Moreno E, Yano H, Cai NS, Sánchez-Soto M, Kumar-Barodia S, Naidu YT, Mallol J, Cortés A, Lluís C, Canela EI, Casadó V, McCormick PJ, Ferré S. Functional selectivity of allosteric interactions within G protein-coupled receptor oligomers: the dopamine D1–D3 receptor heterotetramer. Mol Pharmacol. 2014;86:417–429. [PubMed]
  • Halldner L, Adén U, Dahlberg V, Johansson B, Ledent C, Fredholm BB. The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A receptors. Neuropharmacology. 2004;46:1008–1017. [PubMed]
  • Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013;70:834–851. [PMC free article] [PubMed]
  • Herrera-Marschitz M, Forster C, Ungerstedt U. Rotational behaviour elicited by intracerebral injections of apomorphine and pergolide in 6 hydroxy-dopamine-lesioned rats. I: Comparison between systemic and intrastriatal injections. Acta Physiol Scand. 1985;125:519–527. [PubMed]
  • Herrera-Marschitz M, Casas M, Ungerstedt U. Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses. Psychopharmacology. 1988;94:38–45. [PubMed]
  • Hilbert ML, May CE, Griffin WC., 3rd Conditioned reinforcement and locomotor activating effects of caffeine and ethanol combinations in mice. Pharmacol Biochem Behav. 2013;110:168–173. [PMC free article] [PubMed]
  • Hines DJ, Haydon PG. Astrocytic adenosine: from synapses to psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2014;369:20130594. [PMC free article] [PubMed]
  • Holly EN, Miczek KA. Ventral tegmental area dopamine revisited: effects of acute and repeated stress. Psychopharmacology. 2016;233:163–186. [PMC free article] [PubMed]
  • Holtzman SG, Finn IB. Tolerance to behavioral effects of caffeine in rats. Pharmacol Biochem Behav. 1988;29:411–418. [PubMed]
  • Horger BA, Wellman PJ, Morien A, Davies BT, Schenk S. Caffeine exposure sensitizes rats to the reinforcing effects of cocaine. Neuroreport. 1991;2:53–56. [PubMed]
  • Howe MW, Tierney PL, Sandberg SG, Phillips PE, Graybiel AM. Prolonged dopamine signalling in striatum signals proximity and value of distant rewards. Nature. 2013;500:575–579. [PMC free article] [PubMed]
  • Howell LL, Landrum AM. Effects of chronic caffeine administration onrespiration and schedule-controlled behavior in rhesus monkeys. J Pharmacol Exp Ther. 1997;283:190–199. [PubMed]
  • Hsu CW, Chen CY, Wang CS, Chiu TH. Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice. Psychopharmacology. 2009;204:313–325. [PubMed]
  • Hsu CW, Wang CS, Chiu TH. Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice. J Biomed Sci. 2010;17:4. [PMC free article] [PubMed]
  • Huang RQ, Bell-Horner CL, Dibas MI, Covey DF, Drewe JA, Dillon GH. Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action. J Pharmacol Exp Ther. 2001;298:986–995. [PubMed]
  • Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8:858–859. [PubMed]
  • Hurley MJ, Mash DC, Jenner P. Adenosine A(2A) receptor mRNA expression in Parkinson's disease. Neurosci Lett. 2000;291:54–58. [PubMed]
  • Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, Lang AE. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology. 1999;52:1206–1214. [PubMed]
  • Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci Biobehav Rev. 2010;35:129–150. [PMC free article] [PubMed]
  • Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol Sci. 1996;17:108–113. [PMC free article] [PubMed]
  • Jain R, Holtzman SG. Caffeine induces differential cross tolerance to the amphetamine-like discriminative stimulus effects of dopaminergic agonists. Brain Res Bull. 2005;65:415–421. [PubMed]
  • James JE, Rogers PJ. Effects of caffeine on performance and mood: withdrawal reversal is the most plausible explanation. Psychopharmacology. 2005;182:1–8. [PubMed]
  • James JE, Keane MA. Caffeine, sleep and wakefulness: implications of new understanding about withdrawal reversal. Hum Psychopharmacol. 2007;22:549–558. [PubMed]
  • Jaszyna M, Gasior M, Shoaib M, Yasar S, Goldberg SR. Behavioral effects of nicotine, amphetamine and cocaine under a fixed-interval schedule of food reinforcement in rats chronically exposed to caffeine. Psychopharmacology. 1998;140:257–271. [PubMed]
  • Juliano LM, Evatt DP, Richards BD, Griffiths RR. Characterization of individuals seeking treatment for caffeine dependence. Psychol Addict Behav. 2012;26:948–954. [PMC free article] [PubMed]
  • Justinova Z, Ferre S, Segal PN, Antoniou K, Solinas M, Pappas LA, Highkin JL, Hockemeyer J, Munzar P, Goldberg SR. Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J Pharmacol Exp Ther. 2003;307:977–986. [PubMed]
  • Justinova Z, Ferré S, Barnes C, Wertheim CE, Pappas LA, Goldberg SR, Le Foll B. Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. Psychopharmacology. 2009;203:355–367. [PMC free article] [PubMed]
  • Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev. 1991;16:223–244. [PubMed]
  • Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol. 1994;256:263–268. [PubMed]
  • Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, Justinova Z, Pezzola A, Reggio R, Müller CE, Fuxe K, Goldberg SR, Popoli P, Ferré S. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology. 2003;28:1281–1291. [PubMed]
  • Kendler KS, Myers J, O Gardner C. Caffeine intake, toxicity and dependence and lifetime risk for psychiatric and substance use disorders: an epidemiologic and co-twin control analysis. Psychol Med. 2006;36:1717–1725. [PubMed]
  • Khairnar A, Plumitallo A, Frau L, Schintu N, Morelli M. Caffeine enhances astroglia and microglia reactivity induced by 3,4 methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res. 2010;17:435–439. [PubMed]
  • Kim HF, Hikosaka O. Parallel basal ganglia circuits for voluntary and automatic behaviour to reach rewards. Brain. 2015;138:1776–1800. [PMC free article] [PubMed]
  • Kim DS, Palmiter RD. Adenosine receptor blockade reverses hypophagia andenhances locomotor activity of dopamine-deficient mice. Proc Natl Acad Sci USA. 2003;100:1346–1351. [PubMed]
  • Kim Y, Bolortuya Y, Chen L, Basheer R, McCarley RW, Strecker RE. Decoupling of sleepiness from sleep time and intensity during chronic sleep restriction: evidence for a role of the adenosine system. Sleep. 2012;35:861–869. [PubMed]
  • Klawans HL, Moses H, 3rd, Beaulieu DM. The influence of caffeine on d-amphetamine- and apomorphine-induced stereotyped behavior. Life Sci. 1974;14:1493–1500. [PubMed]
  • Knapska E, Macias M, Mikosz M, Nowak A, Owczarek D, Wawrzyniak M, Pieprzyk M, Cymerman IA, Werka T, Sheng M, Maren S, Jaworski J, Kaczmarek L. Functional anatomy of neural circuits regulating fear and extinction. Proc Natl Acad Sci USA. 2012;109:17093–17098. [PubMed]
  • Lammel S, Lim BK, Malenka RC. Reward and aversion in a heterogeneous midbrain dopamine system. Neuropharmacology. 2014;76(Pt B):351–359. [PMC free article] [PubMed]
  • Lazarus M, Shen HY, Cherasse Y, Qu WM, Huang ZL, Bass CE, Winsky-Sommerer R, Semba K, Fredholm BB, Boison D, Hayaishi O, Urade Y, Chen JF. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci. 2011;31:10067–10075. [PMC free article] [PubMed]
  • Lazenka MF, Moeller FG, Negus SS. Effects of caffeine and its metabolite paraxanthine on intracranial self-stimulation in male rats. Exp Clin Psychopharmacol. 2015;23:71–80. [PMC free article] [PubMed]
  • Lehner KR, Baumann MH. Psychoactive 'bath salts': compounds, mechanisms, and toxicities. Neuropsychopharmacology. 2013;38:243–244. [PMC free article] [PubMed]
  • Leviton A. Behavioral correlates of caffeine consumption by children. Clin Pediatr. 1992;31:742–750. [PubMed]
  • Ljungberg T, Ungerstedt U. Sensory inattention produced by 6-hydroxydopamine-induced degeneration of ascending dopamine neurons in the brain. Exp Neurol. 1976;53:585–600. [PubMed]
  • López-Hill X, Prieto JP, Meikle MN, Urbanavicius J, Abin-Carriquiry JA, Prunell G, Umpiérrez E, Scorza MC. Coca-paste seized samples characterization: chemical analysis, stimulating effect in rats and relevance of caffeine as a major adulterant. Behav Brain Res. 2011;221:134–141. [PubMed]
  • Marczinski CA, Fillmore MT, Henges AL, Ramsey MA, Young CR. Mixing an energy drink with an alcoholic beverage increases motivation for more alcohol in college students. Alcohol Clin Exp Res. 2013;37:276–283. [PMC free article] [PubMed]
  • Marin MT, Zancheta R, Paro AH, Possi AP, Cruz FC, Planeta CS. Comparison ofcaffeine-induced locomotor activity between adolescent and adult rats. Eur J Pharmacol. 2011;660:363–367. [PubMed]
  • Marshall JF, Turner BH, Teitelbaum P. Sensory neglect produced by lateral hypothalamic damage. Science. 1971;174:523–525. [PubMed]
  • Marshall JF, Berrios N, Sawyer S. Neostriatal dopamine and sensory inattention. J Comp Physiol Psychol. 1980;94:833–846. [PubMed]
  • May CE, Haun HL, Griffin WC., 3rd Sensitization and Tolerance Following Repeated Exposure to Caffeine and Alcohol in Mice. Alcohol Clin Exp Res. 2015;39:1443–1452. [PMC free article] [PubMed]
  • McCarley RW. Neurobiology of REM and NREM sleep. Sleep Med. 2007;8:302–330. [PubMed]
  • McCutcheon JE, Ebner SR, Loriaux AL, Roitman MF. Encoding of aversion by dopamine and the nucleus accumbens. Front Neurosci. 2012;6:137. [PMC free article] [PubMed]
  • McKetin R, Coen A, Kaye S. A comprehensive review of the effects of mixing caffeinated energy drinks with alcohol. Drug Alcohol Depend. 2015;151:15–30. [PubMed]
  • Miller R, Beninger RJ. On the interpretation of asymmetries of posture and locomotion produced with dopamine agonists in animals with unilateral depletion of striatal dopamine. Prog Neurobiol. 1991;36:229–256. [PubMed]
  • Minor TR, Hanff TC. Adenosine signaling in reserpine-induced depression in rats. Behav Brain Res. 2015;286:184–191. [PubMed]
  • Misra AL, Vadlamani NL, Pontani RB. Effect of caffeine on cocaine locomotor stimulant activity in rats. Pharmacol Biochem Behav. 1986;24:761–764. [PubMed]
  • Miyashita N, Hikosaka O, Kato M. Visual hemineglect induced by unilateral striatal dopamine deficiency in monkeys. Neuroreport. 1995;6:1257–1260. [PubMed]
  • Morelli M, Carta AR, Jenner P. Adenosine A2A receptors and Parkinson's disease. Handb Exp Pharmacol. 2009;193:589–615. [PubMed]
  • Morikawa H, Morrisett RA. Ethanol action on dopaminergic neurons in the ventral tegmental area: interaction with intrinsic ion channels and neurotransmitter inputs. Int Rev Neurobiol. 2010;91:235–288. [PMC free article] [PubMed]
  • Moscarello JM, LeDoux JE. Active avoidance learning requires prefrontal suppression of amygdala-mediated defensive reactions. J Neurosci. 2013;33:3815–3823. [PMC free article] [PubMed]
  • Müller CE, Ferré S. Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov. 2007;2:1–21. [PubMed]
  • Mumford GK, Holtzman SG. Methylxanthines elevate reinforcement threshold for electrical brain stimulation: role of adenosine receptors and phosphodiesterase inhibition. Brain Res. 1990;528:32–38. [PubMed]
  • Mumford GK, Holtzman SG. Do adenosinergic substrates mediate methylxanthine effects upon reinforcement thresholds for electrical brain stimulation in the rat? Brain Res. 1991;550:172–178. [PubMed]
  • Mumford GK, Neill DB, Holtzman SG. Caffeine elevates reinforcement threshold for electrical brain stimulation: tolerance and withdrawal changes. Brain Res. 1988;459:163–167. [PubMed]
  • Munzar P, Justinova Z, Kutkat SW, Ferré S, Goldberg SR. Adenosinergic modulation of the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology. 2002;161:348–355. 2002. [PubMed]
  • Myers KP, Izbicki EV. Reinforcing and aversive effects of caffeine measured by flavor preference conditioning in caffeine-naive and caffeine-acclimated rats. Physiol Behav. 2006;88:585–596. [PubMed]
  • Navarro G, Aguinaga D, Moreno E, Hradsky J, Reddy PP, Cortés A, Mallol J, Casadó V, Mikhaylova M, Kreutz MR, Lluís C, Canela EI, McCormick PJ, Ferré S. Intracellular calcium levels determine differential modulation of allosteric interactions within G protein-coupled receptor heteromers. Chem Biol. 2014;21:1546–1556. [PubMed]
  • Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev. 1992;17:139–170. [PubMed]
  • Neve KA, Altar CA, Wong CA, Marshall JF. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury. Brain Res. 1984;302:9–18. [PubMed]
  • Nikodijević O, Jacobson KA, Daly JW. Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol Biochem Behav. 1993;44:199–216. [PMC free article] [PubMed]
  • Nunes EJ, Randall PA, Podurgiel S, Correa M, Salamone JD. Nucleus accumbens neurotransmission and effort-related choice behavior in food motivation: effects of drugs acting on dopamine, adenosine, and muscarinic acetylcholine receptors. Neurosci Biobehav Rev. 2013;37:2015–2025. [PubMed]
  • O'Brien MC, McCoy TP, Rhodes SD, Wagoner A, Wolfson M. Caffeinated cocktails: energy drink consumption, high-risk drinking, and alcohol-related consequences among college students. Acad Emerg Med. 2008;15:453–460. [PubMed]
  • O'Neill CE, LeTendre ML, Bachtell RK. Adenosine A2A receptors in the nucleus accumbens bi-directionally alter cocaine seeking in rats. Neuropsychopharmacology. 2012;37:1245–1256. [PMC free article] [PubMed]
  • O'Neill CE, Levis SC, Schreiner DC, Amat J, Maier SF, Bachtell RK. Effects of adolescent caffeine consumption on cocaine sensitivity. Neuropsychopharmacology. 2015;40:813–821. [PMC free article] [PubMed]
  • Orrú M, Guitart X, Karcz-Kubicha M, Solinas M, Justinova Z, Barodia SK, Zanoveli J, Cortes A, Lluis C, Casado V, Moeller FG, Ferré S. Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans. Neuropharmacology. 2013;67:476–484. [PMC free article] [PubMed]
  • Palmiter RD. Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice. Ann N Y Acad Sci. 2008;1129:35–46. [PMC free article] [PubMed]
  • Panek LM, Swoboda C, Bendlin A, Temple JL. Caffeine increases liking and consumption of novel-flavored yogurt. Psychopharmacology. 2013;227:425–436. [PubMed]
  • Parkinson FE, Xiong W, Zamzow CR, Chestley T, Mizuno T, Duckworth ML. Transgenic expression of human equilibrative nucleoside transporter 1 in mouse neurons. J Neurochem. 2009;109:562–572. [PubMed]
  • Peacock A, Pennay A, Droste N, Bruno R, Lubman DI. 'High' risk? A systematic review of the acute outcomes of mixing alcohol with energy drinks. Addiction. 2014;109:1612–1633. [PubMed]
  • Pardo M, Lopez-Cruz L, Valverde O, Ledent C, Baqi Y, Müller CE, Salamone JD, Correa M. Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice. Neuropharmacology. 2012;62:2068–2077. [PubMed]
  • Pereira M, Farrar AM, Hockemeyer J, Müller CE, Salamone JD, Morrell JI. Effect of the adenosine A2A receptor antagonist MSX-3 on motivational disruptions of maternal behavior induced by dopamine antagonism in the early postpartum rat. Psychopharmacology. 2011;213:69–79. [PMC free article] [PubMed]
  • Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse. 2001;9:233–238. [PubMed]
  • Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol. 2002;446:75–82. [PubMed]
  • Pollack AE, Turgeon SM, Fink JS. Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats. Neuroscience. 1997;79:79–93. [PubMed]
  • Pollack AE, Dimitrov KD, Drake JD. Prior treatment (priming) with caffeine sensitizes D2-dopamine-mediated contralateral rotational behavior in 6-hydroxydopamine-lesioned rats. Pharmacology. 2010;86:73–78. [PubMed]
  • Popoli P, Giménez-Llort L, Pezzola A, Reggio R, Martínez E, Fuxe K, Ferré S. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neurosci Lett. 1996;218:209–213. [PubMed]
  • Popoli P, Reggio R, Pèzzola A. Effects of SCH 58261, an adenosine A(2A) receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake. Neuropsychopharmacology. 2000;22:522–529. [PubMed]
  • Porkka-Heiskanen T, Strecker RE, McCarley RW. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience. 2000;99:507–517. [PubMed]
  • Prediger RD, da Silva GE, Batista LC, Bittencourt AL, Takahashi RN. Activation of adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice. Neuropsychopharmacology. 2006;31:2210–2220. [PubMed]
  • Prieto JP, Galvalisi M, López-Hill X, Meikle MN, Abin-Carriquiry JA, Scorza C. Caffeine enhances and accelerates the expression of sensitization induced by coca paste indicating its relevance as a main adulterant. Am J Addict. 2015;24:475–481. [PubMed]
  • Quarta D, Ferré S, Solinas M, You ZB, Hockemeyer J, Popoli P, Goldberg SR. Opposite modulatory roles for adenosine A1 and A2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. J Neurochem. 2004a;88:1151–1158. [PubMed]
  • Quarta D, Borycz J, Solinas M, Patkar K, Hockemeyer J, Ciruela F, Lluis C, Franco R, Woods AS, Goldberg SR, Ferré S. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation. J Neurochem. 2004b;91:873–880. [PubMed]
  • Quiroz C, Orrú M, Rea W, Ciudad-Roberts A, Yepes G, Britt JP, Ferré S. Local control of extracellular dopamine levels in the medial nucleus accumbens by a glutamatergic projection from the infralimbic cortex. J Neurosci. 2016 [PMC free article] [PubMed]
  • Randall PA, Nunes EJ, Janniere SL, Stopper CM, Farrar AM, Sager TN, Baqi Y, Hockemeyer J, Müller CE, Salamone JD. Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. Psychopharmacology. 2011;216:173–186. [PMC free article] [PubMed]
  • Reissig CJ, Strain EC, Griffiths RR. Caffeinated energy drinks. A growing problem. Drug Alcohol Depend. 2009;99:1–10. [PMC free article] [PubMed]
  • Rhoads DE, Huggler AL, Rhoads LJ. Acute and adaptive motor responses to caffeine in adolescent and adult rats. Pharmacol Biochem Behav. 2011;99:81–86. [PubMed]
  • Richard JM, Castro DC, Difeliceantonio AG, Robinson MJ, Berridge KC. Mapping brain circuits of reward and motivation: in the footsteps of Ann Kelley. Neurosci Biobehav Rev. 2013;37:1919–1931. [PMC free article] [PubMed]
  • Rimondini R, Ferré S, Ogren SO, Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology. 1997;117:82–91. [PubMed]
  • Rimondini R, Ferré S, Giménez-Llort L, Ogren SO, Fuxe K. Differential effects of selective adenosine A1 and A2A receptor agonists on dopamine receptor agonist-induced behavioral responses in rats. 1998;347:153–158. [PubMed]
  • Robinson TE, Browman KE, Crombag HS, Badiani A. Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev. 1998;22:347–354. [PubMed]
  • Schechter MD. Caffeine potentiation of amphetamine: implications for hyperkinesis therapy. Pharmacol Biochem Behav. 1977;6:359–361. [PubMed]
  • Schenk S, Horger B, Snow S. Caffeine preexposure sensitizes rats to the motor activating effects of cocaine. Behav Pharmacol. 1990;1:447–445. [PubMed]
  • Schenk S, Valadez A, Horger BA, Snow S, Wellman PJ. Interactions between caffeine and cocaine in tests of self-administration. Behav Pharmacol. 1994;5:153–158. [PubMed]
  • Schenk S, Worley CM, McNamara C, Valadez A. Acute and repeated exposure to caffeine: effects on reinstatement of extinguished cocaine-taking behavior in rats. Psychopharmacology. 1996;126:17–23. [PubMed]
  • Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 1991;57:1062–1067. [PubMed]
  • Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36:241–263. [PubMed]
  • Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013;233:416–422. [PubMed]
  • Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 1999;147:90–95. [PubMed]
  • Simola N, Cauli O, Morelli M. Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. Behav Brain Res. 2006;172:72–79. [PubMed]
  • Solinas M, Ferré S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci. 2002;22:6321–6324. [PubMed]
  • Solinas M, Ferré S, Antoniou K, Quarta D, Justinova Z, Hockemeyer J, Pappas LA, Segal PN, Wertheim C, Müller CE, Goldberg SR. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology. 2005;179:576–586. [PubMed]
  • Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nat Protoc. 2006;1:1194–1206. [PubMed]
  • Starr BS, Starr MS, Kilpatrick IC. Behavioural role of dopamine D1 receptors in the reserpine-treated mouse. Neuroscience. 1987;22:179–188. [PubMed]
  • Steigerwald ES, Rusiniak KW, Eckel DL, O'Regan MH. Aversive conditioning properties of caffeine in rats. Pharmacol Biochem Behav. 1988;31:579–584. [PubMed]
  • Strömberg I, Popoli P, Müller CE, Ferré S, Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur J Neurosci. 2000;12:4033–4037. [PubMed]
  • Szczypka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD. Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. Neuron. 2001;30:819–828. [PubMed]
  • Szymusiak R, McGinty D. Hypothalamic regulation of sleep and arousal. Ann NY Acad Sci. 2008;1129:275–286. [PubMed]
  • Teitelbaum P, Epstein AN. The lateral hypothalamic syndrome: recovery of feeding and drinking after lateral hypothalamic lesions. Psychol Rev. 1962;69:74–90. [PubMed]
  • Temple JL. Caffeine use in children: what we know, what we have left to learn, and why we should worry. Neurosci Biobehav Rev. 2009;33(6):793–806. [PMC free article] [PubMed]
  • Tupala E, Tiihonen J. Dopamine and alcoholism: neurobiological basis of ethanol abuse. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1221–1247. [PubMed]
  • Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol Scand Suppl. 1971a;367:1–48. [PubMed]
  • Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl. 1971b;367:49–68. [PubMed]
  • Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971c;367:69–93. [PubMed]
  • Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl. 1971d;367:95–122. [PubMed]
  • Vanattou-Saïfoudine N, McNamara R, Harkin A. Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators. Br J Pharmacol. 2012;167:946–959. [PMC free article] [PubMed]
  • Van Dort CJ, Baghdoyan HA, Lydic R. Adenosine A(1) and A(2A) receptors inmouse prefrontal cortex modulate acetylcholine release and behavioral arousal. J Neurosci. 2009;29:871–881. [PMC free article] [PubMed]
  • Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, MacLennan S, Granieri E, Borea PA. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB J. 2010;24:587–598. [PubMed]
  • Vertes RP. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse. 2004;51:32–58. [PubMed]
  • Vidal-Gonzalez I, Vidal-Gonzalez B, Rauch SL, Quirk GJ. Microstimulation reveals opposing influences of prelimbic and infralimbic cortex on the expression of conditioned fear. Learn Mem. 2006;13:728–733. [PubMed]
  • Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA. 2011;108:15037–15042. [PubMed]
  • Volkow ND, Wang GJ, Logan J, Alexoff D, Fowler JS, Thanos PK, Wong C, Casado V, Ferre S, Tomasi D. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. Transl Psychiatry. 2015;5:e549. [PMC free article] [PubMed]
  • Voorn P, Vanderschuren LJ, Groenewegen HJ, Robbins TW, Pennartz CM. Putting a spin on the dorsal-ventral divide of the striatum. Trends Neurosci. 2004;27:468–474. [PubMed]
  • White BC, Keller GE., 3rd Caffeine pretreatment: enhancement and attenuation of d-amphetamine-induced activity. Pharmacol Biochem Behav. 1984;20:383–386. [PubMed]
  • Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469–492. [PubMed]
  • Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004;5:483–494. [PubMed]
  • Worley CM, Valadez A, Schenk S. Reinstatement of extinguished cocaine-taking behavior by cocaine and caffeine. Pharmacol Biochem Behav. 1994;48:217–221. [PubMed]
  • Yeomans MR, Spetch H, Rogers PJ. Conditioned flavour preference negatively reinforced by caffeine in human volunteers. Psychopharmacology. 1998;137:401–409. [PubMed]
  • Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci 2006. 2006;7:464–476. [PubMed]
  • Young R, Gabryszuk M, Glennon RA. (−)Ephedrine and caffeine mutually potentiate one another's amphetamine-like stimulus effects. Pharmacol Biochem Behav. 1998;61:169–173. [PubMed]
  • Zancheta R, Possi AP, Planeta CS, Marin MT. Repeated administration of caffeine induces either sensitization or tolerance of locomotor stimulation depending on the environmental context. Pharmacol Rep. 2012;64:70–77. [PubMed]